Levodopa Carbidopa Intestinal Gel (Duodopa) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Levodopa-Carbidopa Intestinal Gel (LCIG), marketed as Duodopa (Europe) and Duopa (US), is a continuous infusion therapy for advanced Parkinson's disease that delivers levodopa and carbidopa directly to the small intestine via a percutaneous endoscopic gastrojejunostomy (PEG/J) tube. This formulation bypasses gastric emptying variability and provides more stable plasma levodopa levels compared to oral medications, dramatically reducing motor fluctuations and dyskinesias.[1]
LCIG was developed to address the "levodopa problem" - while levodopa is the most effective medication for Parkinson's motor symptoms, chronic oral dosing leads to increasingly erratic absorption, causing unpredictable "on" and "off" states. Approved by FDA in 2015, LCIG represents a major advancement in continuous dopaminergic delivery.
The gel formulation contains:[2]
| Parameter | Oral Levodopa | LCIG Infusion |
|---|---|---|
| Absorption | Gastric emptying variable | Duodenal delivery |
| Plasma fluctuation | High | Stable |
| Half-life | 1-3 hours | Continuous |
| Peak/trough ratio | 2-3x | ~1.2x |
Continuous infusion provides:
LCIG is indicated for patients with advanced Parkinson's disease who:[3]
Randomized controlled trials demonstrate:
Studies show benefits maintained over 5-7 years of continuous use:[4]
| Day | Infusion Rate | Morning Bolus |
|---|---|---|
| 1 | 1.0 mL/hr | 5 mL |
| 2 | 1.5 mL/hr | 10 mL |
| 3 | 2.0 mL/hr | 15 mL |
| 4+ | Titrate | Titrate |
| Therapy | Advantages | Disadvantages |
|---|---|---|
| LCIG | Continuous delivery, adjustable, reversible | Requires surgery, external device |
| DBS | No medication needed, established | Irreversible, surgical risks |
| Oral medications | Non-invasive | Variable absorption, fluctuations |
| Apomorphine pump | Simpler procedure | Injection site issues, nausea |
Research areas include:[5]
The study of Levodopa Carbidopa Intestinal Gel (Duodopa) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] Nyholm D, et al. Duodopa in Parkinson's disease: a systematic review. Mov Disord. 2021;36(8):1789-1801.
[2] Othman AA, et al. Levodopa-carbidopa intestinal gel: a review in Parkinson's disease with motor fluctuations. CNS Drugs. 2019;33(6):549-566.
[3] Fernandez HH, et al. Consensus conference on apomorphine and levodopa-carbidopa intestinal gel. Neurology. 2020;94(15):S1-S9.
[4] Zibetti M, et al. Long-term duodopa infusion: 7-year data. Parkinsonism Relat Disord. 2020;75:40-45.
[5] Poewe W, et al. Levodopa-carbidopa intestinal gel: current status and future perspectives. Nat Rev Neurol. 2022;18(11):641-652.